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Pour-Year Efficacy of Cardiac Resynchronization
herapy on Exercise Tolerance and Disease Progression
he Importance of Performing Atrioventricular
unction Ablation in Patients With Atrial Fibrillation
aurizio Gasparini, MD,* Angelo Auricchio, MD, PHD,‡§ François Regoli, MD,* Cecilia Fantoni, MD,‡
ihoko Kawabata, MD,‡ Paola Galimberti, MD,* Daniela Pini, MD,* Carlo Ceriotti, MD,*
doardo Gronda, MD,* Catherine Klersy, MD, MSC,† Simona Fratini, MD,‡ Helmut H. Klein, MD‡
ilan and Pavia, Italy; Magdeburg, Germany; and Lugano, Switzerland
OBJECTIVES The goal of this study was to investigate the effects of cardiac resynchronization therapy
(CRT) in heart failure patients with permanent atrial fibrillation (AF) and the role of
atrioventricular junction (AVJ) ablation.
BACKGROUND Cardiac resynchronization therapy has been proven effective in heart failure patients with
sinus rhythm (SR). However, little is known about the effects of CRT in heart failure patients
with permanent AF.
METHODS Efficacy of CRT on ventricular function, exercise performance, and reversal of maladaptive
remodeling process was prospectively compared in 48 patients with permanent AF in whom
ventricular rate was controlled by drugs, thus resulting in apparently adequate delivery of
biventricular pacing (85% of pacing time), and in 114 permanent AF patients, who had
undergone AVJ ablation (100% of resynchronization therapy delivery). The clinical and
echocardiographic long-term outcomes of both groups were compared with those of 511 SR
patients treated with CRT.
RESULTS Both SR and AF groups showed significant and sustained improvements of all assessed
parameters (model p  0.001 for all parameters). However, within the AF group, only
patients who underwent ablation showed a significant increase of ejection fraction (p 
0.001), reverse remodeling effect (p  0.001), and improved exercise tolerance (p  0.001);
no improvements were observed in AF patients who did not undergo ablation.
CONCLUSIONS Heart failure patients with ventricular conduction disturbance and permanent AF treated
with CRT showed large and sustained long-term (up to 4 year) improvements of left
ventricular function and functional capacity, similar to patients in SR, only if AVJ ablation
was performed. (J Am Coll Cardiol 2006;48:734–43) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.056Cardiology Foundation
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aardiac resynchronization therapy (CRT) is an effective
herapy in symptomatic, drug-refractory heart failure pa-
ients with prolonged QRS and low ejection fraction (1–8).
ong-term results of CRT on exercise tolerance and disease
rogression as evaluated by reversal of maladaptive remod-
ling process are rather limited (4,9,10), and mostly re-
See page 744
orted in patients with sinus rhythm (SR). Permanent or
ersistent atrial fibrillation (AF) is a rather common sup-
aventricular arrhythmia in heart failure patients and is
ssociated with increased morbidity and mortality (11–13).
ome studies have reported significant acute (14–16) and
hort-term (4,9,10) benefits of CRT in patients with AF
nd advanced heart failure, while the long-term effects of
From the *Department of Cardiology IRCCS Istituto Clinico Humanitas
ozzano-Milano, Milan, Italy; †Service of Biometry & Clinical Epidemiology,
RCCS Policlinico San Matteo, Pavia, Italy; ‡Division of Cardiology, University
ospital, Magdeburg, Germany; and the §Department of Cardiology, Fondazione
ardiocentro Ticino, Lugano, Switzerland.a
Manuscript received November 11, 2005; revised manuscript received February 10,
006, accepted March 16, 2006.RT on ventricular function and dimensions in this patient
ubgroup are nearly unknown.
Beta-blocking agents, digoxin, and amiodarone usually
chieve adequate heart rate control at rest, and, thus, relieve
ymptoms in patients with permanent AF. Heart rate
ay be controlled at rest but not entirely during exercise
17). The “ablate and pace” strategy is considered the
reatment of choice in those patients with rapidly con-
ucting AF in which pharmacologic control of heart rate
annot be successfully achieved. This approach provides
mmediate relief of symptoms and large increases in
xercise tolerance (18–21). Whether CRT provides sim-
lar benefits in AF patients treated with medication for
eart rate control (permitting 85% of the biventricular
acing time) or whether performing atrioventricular junc-
ion (AVJ) ablation may provide additional benefits is still
nknown.
The aim of this study was to prospectively investigate the
ong-term effects of CRT on ventricular function, magni-
ude of reverse remodeling, and exercise tolerance in pa-
ients with AF by comparing patients who underwent AVJ
blation with those in whom adequate rate control was
chieved by combining negative chronotropic drugs with
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August 15, 2006:734–43 Cardiac Resynchronization in AFppropriate programming of device settings. These long-
erm echocardiographic and functional changes in patients
ith permanent AF were compared with those in SR
reated with CRT.
ETHODS
atient population. Between August 1995 and December
004, 673 consecutive symptomatic heart failure patients
ere treated with CRT at 2 European centers. All patients
ad a poor systolic left ventricular ejection fraction (LVEF)
35%, ventricular conduction delay (QRS duration 120
s), and were in New York Heart Association (NYHA)
unctional class II despite optimal drug therapy, which
ncluded beta-adrenergic blockers, angiotensin-converting
nzyme inhibitors or angiotensin receptor blockers, diuret-
cs, and spironolactone. All patients had at least 1 hospital-
zation because of heart failure 12 months before device
mplantation.
A total of 162 patients were in permanent AF, and 511
atients were in SR. All permanent AF patients received
egative chronotropic drugs at pre-hospital discharge in
rder to achieve rate control, thus maximizing biventricular
acing delivery. At the 2-month follow-up visit, device
nterrogation of AF patients was performed, and the per-
entage of biventricular pacing time since implantation was
ecorded. An arbitrary cutoff rate of biventricular pacing
85% of pacing time was considered acceptable. When
iventricular pacing percentage was 85%, then AVJ abla-
ion was prospectively performed. Subsequently, in these pa-
ients digoxin and amiodarone were suspended (amiodarone
as continued only if ventricular tachyarrhythmias were
resent), while beta-blocker therapy was maintained.
Due to the potentially serious underlying clinical impli-
ations involved in AVJ ablation (i.e., very slow heart rate
nd pacemaker dependency), the indication for ablation was
ased on careful examination of effective biventricular stim-
lation percentage and directly checked by the 2 most expert
hysicians of each center. Because this approach was not
tandardized clinical care, formal approval was obtained
rom the review boards of each institution. All patients gave
heir written informed consent to undergo the ablation
rocedure under the understanding that irreversible com-
lete AV block would be created with subsequent pace-
Abbreviations and Acronyms
AF  atrial fibrillation
AVJ  atrioventricular junction
CRT  cardiac resynchronization therapy
LVEDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
LVESV  left ventricular end-systolic volume
NYHA  New York Heart Association
SR  sinus rhythm
VRR  ventricular rate regularizationaker dependency. deasures of clinical outcome. Before device implanta-
ion, all patients underwent 12-lead electrocardiogram
ECG) recording, evaluation of NYHA functional class,
ssessment of 6-min walked distance (22), or symptom-
imited peak oxygen consumption (23). Changes during
ollow-up of these functional parameters were expressed
nder a unique parametric index (i.e., the “functional
apacity score” [see Statistical Analysis section for details]).
urthermore, echocardiographic examination was per-
ormed according to American Society of Echocardiography
uidelines (24). The following parameters were collected:
eft ventricular end-diastolic volume (LVEDV) and left
entricular end-diastolic diameter (LVEDD), left ventricu-
ar end-systolic volume (LVESV) and left ventricular end-
ystolic diameter (LVESD), LVEF, and degree (if present)
f mitral valve regurgitation.
In both institutions functional and echocardiographic
valuations were performed in outpatient clinic settings
here the physicians were “blinded” to the AVJ ablation
herapeutic scheme.
Etiology was assessed in all cases by coronary angiography,
nd causes of heart failure amenable to surgery or interven-
ion were corrected at least 6 months before device implan-
ation. Because indication for cardioverter-defibrillator ther-
py changed over time, patients received the most
ppropriate device based on currently available evidence and
uidelines.
evice implantation and programming. Conventional
entricular leads were positioned in the right ventricular
pex in all patients implanted with CRT systems, and
onventional atrial leads were used only in SR patients. In
hose patients in whom implantable defibrillator was nec-
ssary, the defibrillation lead was usually positioned in the
ight ventricular apex. Transvenous left ventricular lead
ositioning was guided by coronary sinus venogram, prefer-
ing a lateral or posterolateral vein as implantation site. In
ase of failure or technical difficulties (phrenic nerve stim-
lation, inability to cannulate the coronary sinus, and so on)
f the transvenous approach, epicardial screw-in or steroid-
luting passive lead was implanted via a limited thoracot-
my. The latter was the elective approach used before
ransvenous lead was routinely available. Follow-up was
erformed at 2, 6, and 12 months after implantation, and
very 12 months thereafter.
In patients with preserved SR, device was programmed in
trial-synchronous sequential pacing; programming of the
V delay was optimized either by echocardiographic
ethod or by invasive measurements (25,6). In patients
ith AF, minimum heart rate was usually set at 70 beats/
in (80 beats for 2 weeks after AVJ ablation) (26).
aximum rate was set at 85% of the theoretical maximum
eart rate; the rate adaptive response was turned on, and
entricular rate stabilization and/or ventricular rate regula-
ion (VRR) was activated when available. Ventricular rate
egulation was activated on the “max” value that usually
etermined a pacing rate 8% to 10% faster than intrinsic
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Cardiac Resynchronization in AF August 15, 2006:734–43eart rate. It was assumed that careful programming of
evice settings combined with prescription of negative
hronotropic drugs would allow achievement of adequate
eart rate control for effective biventricular pacing.
Biventricular pacing percentage was accurately assessed
hrough device counters’ analysis performed at the 2-month
isit. In early generation devices, correct evaluation of the
ffective percentage of left ventricle stimulation was some-
imes difficult due to the presence of dual cathodal systems.
he absence of dedicated AF algorithms, in these devices,
nly rarely permitted to obtain a percentage of biventricular
acing 85%. New and improved device technology, by
sing separate right ventricular and left ventricular channels,
RR, and the capability of detecting triggered beats, has
arkedly increased the accuracy of counters, and has per-
itted the achievement of higher percentages of biventricu-
ar pacing. Nonetheless, even in the most recent devices, the
ossible presence of fusion or pseudofusion beats may
verestimate the percentage of true and effective biventricu-
ar stimulation.
efinition of responders. Responders to CRT were con-
idered those patients who showed a reduction in LVESV
10% relative to baseline (27). Assessments for responder
tatus were performed at 6, 12, and every 12 months
hereafter. Repetitive response assessments were obtained in
ll patients who reached 1-year follow-up or more.
tatistical analysis. Descriptive statistics were reported as
ean and SD for continuous variables, unless skewed when
edian and quartiles were computed. Categorical variables
ere summarized as absolute and relative frequencies (%).
aseline characteristics of patients with SR and AF, with
nd without AVJ ablation, were compared by means of
tudent t test or Mann-Whitney U test for continuous
ariables and Fisher exact test for categorical variables.
hanges over time of cardiac performance, and role of AF
r of AVJ ablation, were assessed by fitting a generalized
inear regression model. Intrapatient correlation due to the
epeated measures design was accounted for by calculating
uber-White robust standard errors. The following possi-
le confounders were also included in the models: center,
ge, gender, diagnosis of coronary artery disease, and base-
ine left ventricle ejection fraction. To evaluate whether
hanges in time were different between groups, interactions
etween time and AF or between time and AVJ ablation
ere also assessed. Functional assessment was performed
ither by means of 6-min walking test or by means of
ymptom-limited peak oxygen consumption. The choice of
erforming one test over the other was mainly determined
y the availability of the equipment for cardiopulmonary
esting: in the earlier phase of the study, 6-min walking was
revalently performed, while the more complete and sophis-
icated cardiopulmonary test was performed in the later
hase. In the single patient, the same criteria to assess
unctional capacity at baseline were utilized throughout
ubsequent follow-up. In order to obtain a unique functional (ssessment index for the entire case series, both variables
ere converted to a 1 to 100 scale, by applying the following
ransformation: functional capacity score  100  (ob-
erved value  minimum observed value)/range of observed
alues (28).
All tests were 2-sided. A p value 0.05 was retained as
ndicative of statistical significance. Bonferroni correction
or multiple tests was used for post-hoc comparisons over
ime (5 comparisons). Stata 8 (Stata Corp., College Station,
exas) was used for computation.
ESULTS
aseline characteristics of AF and SR patients enrolled at
ach center did not statistically differ. Some statistically
ignificant, yet probably clinically less relevant, differences
ppeared when the populations of the 2 centers were
ombined. However, the parameters accounting for differ-
nces were evenly distributed between the 2 centers. Age
62  9.0 years vs. 65  10 years, p  0.0001), NYHA
unctional class III to IV (98% vs. 86%, p 0.0001), LVEF
23.7  5.8% vs. 27.8  6.2%, p  0.001), and LVEDD
69  9 mm vs. 66  9 mm, p  0.0001) differed between
he 2 centers. After 2 months of CRT, careful evaluation of
evice counters revealed continuous biventricular pacing
ctivity (mean 98.5  1.7%) in SR patients. A low propor-
ion of spontaneous intrinsic ventricular beats was detected,
ost likely due to ventricular premature beats. In no case
as the proportion of ventricular premature beats found to
e 5%. In 114 patients with AF, a global biventricular
ercentage of 85% (mean 74.6  5.2%) was detected
hich, by prospective study design, led to AVJ ablation. At
he following 6-month control after ablation, device
ounters revealed full biventricular pacing effectiveness, with
ercentages nearing 100% (mean 98.4  2.1%). In the
emaining 48 patients with AF, the combination of pro-
rammed device features (minimum and maximum heart
ate, rate adaptive response up to 85% of the theoretical
aximum heart rate, and VRR) and negative chronotropic
rug therapy determined 85% biventricular pacing per-
entage (mean 88.2  3.1%) and satisfactory heart rate
ontrol; mean resting heart rate was 76.4 5.1 beats/min in
his patient subgroup.
linical outcome of SR and AF patients. Table 1 shows
he baseline characteristics of patients with SR and AF.
verall, AF patients were significantly older (p  0.002),
ore frequently men (p  0.019), clinically more compro-
ised, with a higher mean NYHA functional class, and
oorer functional capacity (functional capacity score was
ifferent, p  0.014), but presented less frequently with
oronary artery disease (p  0.029). More SR patients were
mplanted with a device combining CRT and defibrillation
p  0.036). Pharmacologic agents with negative chrono-
ropic effect were significantly more utilized in AF patients
p  0.0001) (Table 1).
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August 15, 2006:734–43 Cardiac Resynchronization in AFDuring a mean follow-up of 25.2  18 months, SR and
F patients showed highly significant and similar improve-
ents in functional capacity, magnitude of reverse remod-
ling, left ventricular systolic function, and NYHA func-
ional class (Table 2). The greatest changes in LVEF,
everse remodeling, and NYHA functional class occurred
ithin the first 6 months and continued for up to 4 years in
oth groups. Moreover, there was an increase in walked
istance by around 140 m and peak oxygen consumption by
round 3 ml/kg/min at 6 months that remained stable
uring the follow-up, reflected by significant improvements
f functional capacity score in both groups over 48 months.
he proportion of responders to CRT at 1 year was similar
or both groups (SR 69% vs. AF 60%, p  0.166) and
emained fairly stable over time. Over 4 years of follow-up
VEF of non-responders decreased by a mean value of 3.3 
.7 points compared with baseline. In responder patients, in
ontrast, a consistent and significant increase of mean LVEF
10.8  9.1 points) was observed.
omparison of effects within the AF group. The baseline
haracteristics of AF patients treated with and without AVJ
blation are shown in Table 3. No significant difference was
resent at baseline between the 2 groups. Antiarrhythmic
rugs as well as other pharmacologic agents, such as
eta-blockers (no AVJ ablation 81.3% vs. AVJ ablation
4.2%, p  0.65) and angiotensin-converting enzyme in-
ibitors (no AVJ ablation 95.8% vs. AVJ ablation 93.0%,
 0.72), were utilized by a similar proportion of patients
n each group. In the 2 months after implantation and
receding the assessment phase of percentage of biventricu-
Table 1. Baseline Characteristics of SR and A
Follow-up (months)*
Age (yrs)†
Male gender (%)†
Functional NYHA functional class III–IV (%)‡
QRS duration (ms)†
Coronary artery disease (%)‡
LVEF (%)†
LVEDD (mm)†
LVESV (ml)†
Peak oxygen consumption (ml/min/kg)†
6-min walking distance (m)†
Functional capacity score†
CRT with a defibrillator (%)‡
Beta-blockers (%)‡
ACE inhibitors (%)‡
Antialdosteronic agents (%)‡
Diuretics (%)‡
Negative chronotropic drugs (%)‡
Lead position: lateral or posterolateral region (%)‡
*Median and 25th–75th percentile (Mann-Whitney U test);
ACE  angiotensin-converting enzyme; AF  atrial fibri
ventricular end-diastolic diameter; LVEF  left ventricular
NYHA  New York Heart Association; SR  sinus rhythmar pacing time, virtually all AF patients (99%) were in pherapy with negative chronotropic drugs (Table 1). After
dequate and conventional loading doses, mean daily main-
enance dose of amiodarone was 185 mg, of digoxin was
.185 mg, and of carvedilol was 17.5 mg. By prospective
esign, patients who failed the 85% biventricular pacing
riteria underwent AVJ ablation, and, subsequently, negative
hronotropic drug therapy was discontinued; amiodarone was
ontinued only in cases who presented ventricular tachyar-
hythmias, while beta-blocker was maintained.
Only the ablated group of patients showed a significant
mprovement of LVEF (p  0.001), LVESV (p  0.001),
nd exercise capacity (p 0.001) over the follow-up period.
agnitude of improvement of LVEF, LVESV, NYHA
unctional class, and of functional capacity were significantly
arger for ablated patients (Table 4, Fig. 1). Moreover, there
as a significantly higher proportion of responder patients
t 12 months in the ablated group (68%) compared with the
on-ablated group (18%) (p  0.001); this significant
ifference was maintained throughout follow-up (p 
.001) (Fig. 2). When considering patients who died, the
ifference in proportion of responders between the 2 groups
emained highly significant (p  0.001; odds ratio 11.12,
5% confidence interval 4.03 to 25.35).
ISCUSSION
his is the first long-term, prospectively designed study
emonstrating the importance of AVJ ablation in AF
ients
SR
(n  511)
AF
(n  162) p Value
6.1 (12.4–42.2) 24.6 (12.7–42.2) 0.562
3.4 (10.0) 66.0 (8.3) 0.002
95 (77.3) 139 (85.8) 0.019
52 (89.7) 154 (96.9) 0.003
5.3 (29.5) 165.0 (35.5) 0.915
41 (47.2) 60 (37.1) 0.029
6.0 (7.0) 26.3 (6.7) 0.647
7.0 (9.0) 66.0 (8.8) 0.259
96 (53) 186 (45) 0.062
3.1 (2.8) 12.1 (2.2) 0.005
32 (117) 311 (107) 0.122
3.4 (7.3) 29.6 (6.5) 0.014
99 (58.5) 79 (48.8) 0.036
24 (83.1) 135 (83.3) 1.000
60 (90.4) 152 (93.8) 0.204
67 (52.5) 85 (52.5) 1.000
49 (88.2) 148 (91.4) 0.314
35 (85.1) 160 (98.7) 0.0001
54 (89) 142 (88) 0.885
and (SD) (Student t test); ‡number (%) (Fisher exact test).
; CRT  cardiac resynchronization therapy; LVEDD  left
n fraction; LVESV  left ventricular end-systolic volume;F Pat
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Cardiac Resynchronization in AF August 15, 2006:734–43agnitude of benefit with CRT was similar between SR
nd permanent AF. However, among patients with perma-
ent AF, only those patients undergoing ablation of AVJ
emonstrated a significant symptomatic benefit and im-
rovement of left ventricular function. The symptomatic
able 2. Sequential Changes of Left Ventricular Function and D
ssessed by Functional Capacity Score in Patients With SR or A
nd Etiology
SR
Mean (SD)
AF
Mean (SD)
Mod
p Va
VEF (n  673) 0.0
Baseline (%) 26.0 (7.0) 26.3 (6.7)
6 months 31.6 (10.7) 30.5 (11.7)
12 months 33.5 (12.2) 33.8 (13.3)
24 months 34.4 (13.5) 36.1 (14.4)
36 months 35.8 (14.3) 38.0 (14.7)
48 months 33.2 (13.8) 35.2 (14.7)
VESV (n  673) 0.0
Baseline (mm) 196 (53) 186 (45)
Change from baseline
At 6 months (%) 16 (19) 12 (17)
At 12 months (%) 23 (21) 14 (25)
At 24 months (%) 26 (24) 21 (19)
At 36 months (%) 31 (22) 27 (18)
At 48 months (%) 31 (25) 25 (19)
YHA functional class
(n  673)
0.0
Baseline (% III–IV) 90 97
6 months 28 42
12 months 15 29
24 months 11 22
36 months 9 14
48 months 12 24
unctional capacity score
(n  673)
0.0
Baseline 33.4 (7.3) 29.6 (6.5)
6 months 40.7 (8.1) 37.4 (8.2)
12 months 42.6 (8.1) 40.1 (8.2)
24 months 44.3 (7.3) 42.1 (7.8)
36 months 45.4 (8.2) 41.4 (8.0)
48 months 43.0 (7.8) 40.4 (9.1)
Model p value (overall difference between patients with SR and with AF over time [m
etween patients with SR and patients with AF; §for Bonferroni correction, statis
5 comparisons); p value for assessing the interaction of rhythm (SR/AF) and time.
Abbreviations as in Table 1.
Table 3. Baseline Characteristics of AF Patien
AF No
Age (yrs)*
Male gender (%)†
NYHA functional class III–IV (%)†
QRS duration (ms)* 1
Coronary artery disease (%)†
LVEF (%)*
LVEDD (mm)*
LVESV (ml)*
Peak oxygen consumption (ml/min/kg)*
6-min walking distance (m)*
Functional capacity score‡
Negative chronotropic drugs (%)†*Mean and SD (Student t test); †number (%) (Fisher exact test); ‡
AVJ  atrioventricular junction; other abbreviations as in Tablenefit, improvement of exercise tolerance, and reversal of
aladaptive remodeling process provided by CRT was
aintained up to 4 years after therapy initiation. Whether
hese beneficial effects will result in different survival out-
ome remains to be addressed.
sion, NYHA Functional Class, and Physical Performance as
nalysis Adjusted for Center, Baseline LVEF, Age, Gender,
AF
p Value†
Time Change p Value‡
and Post-Hoc p Values§
Time-Rhythm
Interaction p Value
0.429 0.001‡ 0.089
6 vs. baseline 0.001§
12 vs. 6 months 0.001§
24 vs. 12 months 0.001§
36 vs. 24 months 0.006§
48 vs. 36 months 0.015§
0.452 0.001‡ 0.828
6 vs. baseline 0.001§
12 vs. 6 months 0.001§
24 vs. 12 months 0.002§
36 vs. 24 months 0.040§
48 vs. 36 months 0.761§
0.001 0.001 0.644
6 vs. baseline 0.001§
12 vs. 6 months 0.001§
24 vs. 12 months 0.003§
36 vs. 24 months 0.093§
48 vs. 36 months 0.241§
0.009 0.001 0.789
6 vs. baseline 0.001§
12 vs. 6 months 0.001§
24 vs. 12 months 0.001§
36 vs. 24 months 0.074§
48 vs. 36 months 0.407§
ects]); †p value for changes over time in the whole case series; ‡p value for differences
gnificance for post-hoc tests: p  0.01 for comparison of consecutive assessments
ith and Without AVJ Ablation
Ablation
48)
AF  AVJ Ablation
(n  114) p Value
6.3) 66.8 (9.0) 0.054
83.3) 99 (86.8) 0.624
100) 106 (95.5) 0.323
32.0) 162.0 (36.5) 0.105
39.6) 41 (36.0) 0.723
5.7) 26.8 (7.1) 0.133
8.4) 65.3 (8.9) 0.084
50) 182 (49) 0.101
2.2) 12.1 (2.1) 0.892
72) 311 (68) 0.973
6.9) 31.7 (7.1) 0.932
100) 112 (98) 1.0imen
F: A
el
lue*
01
01
01
01
ain eff
tical sits W
AVJ
(n 
64.1 (
40 (
48 (
72.1 (
19 (
25.1 (
67.9 (
196 (
12.1 (
313 (
24.6 (
48 (adjusted for mode of functional assessment.
e 1.
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August 15, 2006:734–43 Cardiac Resynchronization in AFong-term efficacy of CRT. Our findings expand previous
nowledge of short-term improvement, showing how the
enefits are sustained up to 4 years after the initiation of
RT. Overall, CRT promoted reversal of maladaptive
emodeling process of the left ventricle as shown by in-
reases in LVEF and decreases in LVESV. These changes
ere similar both in patients with AF and SR.
Improvements in left ventricular function and exercise
apacity observed in our group of patients with SR were
imilar or even greater than those reported in several
rospective, randomized trials (4,10,29). Moreover, our
ndings showed that, in SR patients, CRT has a favorable
ffect up to 4 years after therapy initiation.
Our long-term data in patients with AF are novel, and
howed a continuous increase of LVEF and LVESV reduc-
ion over a 4-year time span. Our results in these patients
re partially in disagreement with those reported by
eclercq et al. (29) and by Linde et al. (4). Leclercq et al.
29) showed that, despite improvement of exercise tolerance
able 4. Sequential Changes of Left Ventricular Function and D
ssessed by Functional Capacity Score in Patients With and Wit
ge, Gender, and Etiology
Variables
AF no AVJ
Ablation
(n  48)
AF  AVJ
Ablation
(n  114)
Mo
p V
VEF (n  162) 0
Baseline 25.1 (5.7) 26.8 (7.1)
6 months 22.4 (8.1) 33.9 (11.4)
12 months 23.7 (9.4) 37.1 (12.7)
24 months 24.1 (10.8) 39.7 (13.4)
36 months 25.8 (10.6) 41.7 (13.8)
48 months 25.0 (12.8) 39.5 (13.6)
VESV (n  162) 0
Baseline (mm) 196 (50) 182 (49)
Changes from baseline
At 6 months (%) 2 (11) 16 (18)
At 12 months (%) 3 (14) 18 (28)
At 24 months (%) 1 (17) 27 (18)
At 36 months (%) 5 (14) 34 (18)
At 48 months (%) 2 (20) 36 (16)
YHA functional class
(n  162)
0
Baseline (% III–IV) 100 96
6 months 87 23
12 months 59 19
24 months 36 18
36 months 31 9
48 months 43 16
unctional capacity score
(n  162)
0
Baseline 24.6 (3.5) 31.7 (7.1)
6 months 25.2 (4.1) 42.5 (8.1)
12 months 27.5 (4.8) 44.2 (8.0)
24 months 28.6 (5.1) 46.3 (7.3)
36 months 28.8 (4.1) 45.2 (7.9)
48 months 25.3 (2.5) 46.5 (8.9)
Model p value (overall difference between patients with and without AVJ ablation [m
etween patients with and without AVJ ablation; §for Bonferroni correction, statis
5 comparisons); p value for assessing the presence of interaction of ablation (yes/n
AVJ  atrioventricular junction; other abbreviations as in Table 1.n both patients with AF and SR, a significant amelioration cf LVEF was obtained exclusively in AF patients. Linde et
l. (4) reported only modest, non-significant changes in left
entricular dimensions 12 months after initiation of CRT
espite significant reduction of mitral valve regurgitation in
oth SR and AF patients. Difference in sample size, longer
ollow-up, and management strategy of AF patients (AVJ
blation) may account for differences between our results
nd the findings by others (4,29). One recent study (10)
eported some preliminary data on 30 heart failure patients
ith AF treated with CRT, a proportion of whom under-
ent AVJ ablation. A greater improvement of quality of life
nd a trend towards better response at 6 months follow-up
n the subgroup that underwent AVJ ablation was observed.
Cardiac resynchronization therapy enhanced exercise ca-
acity assessed by 6-min walking distance or peak oxygen
onsumption. The long-lasting effect of CRT on exercise
olerance cannot be attributed to a placebo effect, given the
act that this effect tends to wane over time. Although none
f the patients of this study underwent an additional
sion, NYHA Functional Class, and Physical Performance as
AVJ Ablation: Analysis Adjusted for Center, Baseline LVEF,
Ablation
p Value†
Time Change p Value‡
and Post-Hoc p Values§
Time AVJ Ablation
Interaction p Value
0.001 0.001‡ 0.001
6 vs. baseline 0.001§
12 vs. 6 months 0.001§
24 vs. 12 months 0.001§
36 vs. 24 months 0.474§
48 vs. 36 months 0.194§
0.001 0.001‡ 0.025
6 vs. baseline 0.001§
12 vs. 6 months 0.014§
24 vs. 12 months 0.151§
36 vs. 24 months 0.803§
48 vs. 36 months 0.421§
0.001 0.001‡ 0.644
6 vs. baseline 0.001§
12 vs. 6 months 0.008§
24 vs. 12 months 0.129§
36 vs. 24 months 0.141§
48 vs. 36 months 0.326§
0.001 0.001‡ 0.001
6 vs. baseline 0.001§
12 vs. 6 months 0.013§
24 vs. 12 months 0.001§
36 vs. 24 months 0.649§
48 vs. 36 months 0.430§
ects]); †p value for changes over time in the whole case series; ‡p value for differences
gnificance for post-hoc tests: p  0.01 for comparison of consecutive assessments
time.imen
hout
del
alue*
.001
.001
.001
.001
ain eff
tical siontrolled training program, the continuous increase of
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raining effect occurred after device implantation.
mportance of AVJ ablation in AF patients with CRT.
ur treatment approach in heart failure patients with AF
as novel and different from the standard “ablate and pace”
trategy. This latter approach is usually indicated in patients
ho have rapidly conducting AF not well controlled by
harmacologic therapy, eventually presenting with heart
ailure. Patients enrolled in these studies (18–21) were
sually older, had an LVEF usually of around 40%, a shorter
istory of heart failure, and were receiving less medication
or heart failure and more antiarrhythmic drugs. Conversely,
ur population (both SR and AF patients) was younger and
ad severely depressed left ventricular function; the reason
or ablation was not drug-refractory control of ventricular
ate during AF, but rather suboptimal biventricular pacing.
efore ablation, the mean resting heart rate was about 80
eats/min, which was considerably lower than the ventric-
lar rate of patients who undergo typical “ablate and pace”
trategy, thus greatly reducing the likelihood that heart
ailure could be due to underlying tachycardiomyopathy.
We observed that the effect of biventricular pacing, even
hen proven to be above 85% of pacing time, was not as
ffective as 100% of biventricular pacing time achievable
igure 1. This figure presents sequential changes of left ventricular ejectio
eft ventricular end-systolic volume (C) in patients with sinus rhythm (SR
blation. Significance values within the single groups are given in Tables
eaching the different follow-up visits and the number of deaths that occunly by ablating the AVJ. Drugs such as beta-blocking pgents, digoxin, or amiodarone (mostly in combination)
ere given for the first months to all our AF patients in
rder to achieve adequate rate control, and, consequently,
dequate percentage of biventricular pacing. We prospec-
ively designed to ablate the AVJ in every patient who, at the
-month follow-up visit, presented a percentage of effective
iventricular pacing 85%. Based on this criterion, a
inority of patients (only 29%) had satisfactory heart rate
ontrol achieved by drugs. These patients were similar in
any clinical and echocardiographic parameters to patients
ho underwent ablation. Digoxin and amiodarone were
iscontinued in patients who underwent AVJ ablation
amiodarone was continued only if ventricular tachyarrhyth-
ias were present), while beta-blockers were maintained.
The percentage of “responders” in the ablated group was
ore than 3-fold that of the non-ablated AF group. The
efinition of responder to CRT differs widely in the
iterature (27,30–33). The proportion of non-responders in
oth SR and AF was either similar or somewhat lower than
hat has been previously reported (2,30).
Long-term effects of CRT on exercise tolerance, NYHA
unctional class, ventricular function, and magnitude of
everse remodeling in patients with AF in whom the mean
evice-derived percentage of biventricular pacing was ap-
tion (A), exercise capacity (functional capacity score) (B), and changes in
atrial fibrillation (AF) with and without atrioventricular junction (AVJ)
4. Also included (D) below the legend are the total number of patients
in the time interval since last follow-up.n frac
) and
2 andarently well controlled (85% of daily time) by drugs was
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August 15, 2006:734–43 Cardiac Resynchronization in AFignificantly lower than those of patients in whom ablation
as performed (ensuring 100% CRT delivery). In contrast,
ffective and full biventricular capture achieved through
VJ ablation conferred marked improvements of both
VEF and left ventricular dimensions implying a possible
rognostic benefit, because both these parameters have been
orrelated with favorable prognosis in heart failure patients
ndergoing CRT (27).
Several reasons may account for the better functional
utcome of patients who have been rendered pacemaker-
ependent by ablation. First and foremost, it is likely that
omplete rhythm regularization obtained through ablation,
y optimizing diastolic and systolic phases of the cardiac
ycle, improved global cardiac mechanics (21,34). Without
blation, relatively high biventricular pacing percentage was
chieved at a cost of higher mean heart rates with deleteri-
us effects on diastolic performance (35,36). Then, during
xercise, heart rate control was usually difficult (17). The
ccurrence of fusion or “pseudofusion” beats between in-
rinsic conducted and paced beats (even obtained with the
RR setting) tends to overestimate true effective CRT
elivery as determined by the surrogate parameter of per-
entage of biventricular stimulation time and may provide a
ess efficient resynchronization effect compared with full,
egular, and continuous biventricular pacing. Taking into
ccount the interference of intrinsic beats, a more plausible
stimate of effective “CRT dose” may be lower than the
evice-derived biventricular pacing percentage, which aver-
ged 88%. In this way, the outcome observed for the AF
opulation not undergoing AVJ ablation may be easier to
omprehend.
A growing amount of evidence has reported the efficacy
f the anatomic (37) or the electrophysiological ablation
pproach (38) in the treatment of paroxysmal and persistent
igure 2. Percentage of responders to cardiac resynchronization therapy
CRT) at different follow-up times are presented. The open bars refer to
inus rhythm patients, the ruled bars relate to atrial fibrillation with
trioventricular junction ablation, and, finally, the solid bars refer to atrial
brillation without atrioventricular junction ablation. There was a signifi-
antly higher proportion of responders in patients with sinus rhythm or
trial fibrillation with atrioventricular junction ablation compared with
trial fibrillation patients without atrioventricular junction ablation.F. In particular, the effectiveness of the electrophysiolog- tcal strategy has been proven in a limited patient population
ith mild heart failure disease (38). These approaches may
e considered in the future among the different possible
reatment approaches to AF in heart failure patients.
tudy limitations. The relatively small number of patients
n the non-ablated group may in some way bias the outcome
f the study. Nevertheless, the intriguing findings of con-
istent low benefit in non-ablated AF patients suggests that,
ven by enlarging the patient cohort, the absolute increase of
eft ventricular function would likely remain small. The
ercentage cutoff of biventricular pacing for indicating AVJ
blation was arbitrarily selected. It seemed reasonable to
ssume that 85% of biventricular pacing rate was enough; on
he contrary, this relatively high pacing time was not
ufficient in detecting any substantial benefit from CRT.
Percentage of biventricular stimulation probably overes-
imates effective biventricular capture, particularly because
ercentage of pacing does not objectively account for the
roblem of fusion and pseudofusion between intrinsic and
aced beats. In fact, 24-h Holter ECG monitoring per-
ormed in some non-ablated AF patients implanted with
RT systems confirmed some discordance between true
ffective biventricular capture and the percentage of biven-
ricular stimulation time derived from device counters; in
hese cases, while device-derived percentage of biventricular
ime was 85%, effective biventricular capture detected at
4-h monitoring resulted lower. This limitation, however,
oes not change the very relevant clinical message of the
resent work: AVJ ablation in heart failure patients with
ermanent AF treated with CRT maximized CRT delivery
etter than any other approach.
The populations studied at the 2 centers differed in terms
f baseline LVEF. Although some interobserver variability
hen evaluating LVEF by echocardiography cannot be
ompletely dismissed, 1 center started CRT very early on,
hen extremely compromised patients with very low value
f LVEF were considered “ideal” candidates for the therapy.
The limits posed by the differences within the population
ere overcome by the statistical analysis that considered
ossible confounding effects of center, gender, age, etiology,
nd baseline LVEF in the fitted models. Moreover, the
hoice of using a general linear model for the analysis
llowed the efficient use of all the information available at
ach time point.
Because patients were consecutively enrolled, a few pa-
ients in NYHA functional class II were included (10% in
R and 3% in the AF groups). The positive results observed
n the global population cannot permit any conclusive
tatement on the improvement of symptoms and exercise
olerance in the NYHA functional class II patient subgroup.
Finally, the declining number of patients over follow-up
ay represent a limitation. But this is the case of all
bservational cohort studies. All the available patients and
isits were included, and no patient was lost to follow-up.
hus, the possibility of informative censoring was restricted
o patients dying, who, however, were considered in the
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Cardiac Resynchronization in AF August 15, 2006:734–43nalysis as long as their data were available. We are aware of
his possible bias, and in this sense we might have overes-
imated the magnitude of changes in time of the parameters
valuated, but potentially not of the role of AF and of AVJ
blation. To indirectly deal with this problem, we assessed
he role of AF and of AVJ ablation on the response to CRT,
oth while excluding and including cardiac death as non-
esponse, and conclusions did not differ substantially.
onclusions. Cardiac resynchronization therapy induced a
emarkable, progressive, and persistent long-term improve-
ent of left ventricular function and functional capacity in
eart failure patients with AF. This long-term improvement
rogressed in parallel to that observed in patients with SR.
he combination of CRT and AVJ ablation is a superior
reatment strategy in heart failure patients with AF. Large
andomized studies would be useful to further confirm these
esults.
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